List view / Grid view



Beat In-Albon new COO of the life science ingredients sector

1 June 2012 | By

Starting on 1 June 2012, Beat In-Albon will join Lonza as COO of the Life Science Ingredients Sector and become a member of the Management Committee, replacing Harry Boot. Beat In-Albon brings broad industry experience to his role, having worked for Lonza already from 1983-2006, where he was Head of…

Implementing chemometrics in late stage development and manufacturing

26 April 2012 | By Geir Rune Flåten, former Chemometrician Leader in Global Manufacturing and Supply at GlaxoSmithKline

Chemometrics was defined as a research area in 1974 and developed rapidly through the following decades in parallel with the fast paced improvement in analytical technologies and computational power for lab instruments and sensors. Chemometrics is essentially the translation of measured signals characterising a sample or a process into meaningful…

Discovery chemistry outsourcing

26 April 2012 | By Luigi La Vecchia, Director of the Preparations Laboratories, Novartis Institute for Biomedical Research

In 2002, Novartis decided to create a new research centre in Cambridge, MA. This was accompanied by a significant increase in headcount in medicinal chemistry. Within two years, this resulted in a strongly increased demand for prep-scale synthesis which in turn led to priority issues and to prolonged turnaround times…

Outsourcing in early drug discovery: Evolution and opportunities

26 April 2012 | By Jayshree Mistry, Paul Lloyd, Kevin Oliver and Peter North, GlaxoSmithKline R&D and Duncan Judd, Awridian

This article describes the evolution of outsourcing within early drug discovery at GlaxoSmithKline (GSK), specifically for chemistry services applied to developing a compound from the screening hit through lead optimisation. It will touch on different business models, factors to consider when selecting potential CROs, the benefits of outsourcing and CRO…

Rapid micro methods and EMA’s post approval change management protocol

26 April 2012 | By Michael J. Miller, President, Microbiology Consultants, LLC

This is the second paper in our continuing series on Rapid Microbiological Methods that will appear in European Pharmaceutical Review during 2012. In my last article, we discussed a number of myths or misconceptions associated with the validation and implementation of rapid microbiological methods (RMMs). In fact, most RMM myths…


9 March 2012 | By Accelrys

Learn more about HEOS® by SCYNEXIS - a SaaS workspace in which multiple, disparate companies, academic collaborators or CROs can exchange scientific data securely and in real-time.

Send this to a friend